Skip to main content

Myocarditis clinical trials at University of California Health

2 research studies open to eligible people

Showing trials for
  • Abatacept in Immune Checkpoint Inhibitor Myocarditis

    open to eligible people ages 18 years and up

    The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.

    at UCLA

  • MYTHS - MYocarditis THerapy With Steroids

    open to eligible people ages 18-69

    This is a phase III, multi-center international, single blind randomized controlled trial to test the efficacy of pulsed intravenous (IV) methylprednisolone versus standard therapy on top of maximal support in patients with Acute myocarditis (AM).

    at UCSD

Our lead scientists for Myocarditis research studies include .

Last updated: